Published in final edited form as:

Bioessays. 2012 February ; 34(2): 135–141. doi:10.1002/bies.201100121.

Shadow enhancers: Frequently asked questions about distributed *cis*-regulatory information and enhancer redundancy

Scott Barolo

Department of Cell & Developmental Biology, University of Michigan Medical School, Ann Arbor, MI, USA

Abstract

This review, in the form of a FAQ, addresses outstanding questions about “shadow enhancers”, quasi-redundant *cis*-regulatory elements, and their proposed roles in transcriptional control. Questions include: What exactly are shadow enhancers? How many genes have shadow/redundant/distributed enhancers? How redundant are these elements? What is the function of distributed enhancers? How modular are enhancers? Is it useful to study a single enhancer in isolation? In addition, a revised definition of “shadow enhancers” is proposed, and possible mechanisms of shadow enhancer function and evolution are discussed.

Keywords

cis-regulatory elements; enhancers; evolution; genomics; transcriptional regulation

INTRODUCTION

Q: What exactly are shadow enhancers?

A: Enhancers are *cis*-regulatory elements that control the spatiotemporal patterns and quantitative levels of gene transcription. They are composed of clusters of binding sites for transcription factors (TFs), each of which contributes to either the activation or repression of transcription. In multicellular organisms, the combination of TFs bound to an enhancer largely determines its target gene’s response to developmental, physiological, or environmental signals. The functional definition of an enhancer will be discussed further below; for a more in-depth examination of enhancers in the context of animal development, see [1].

The phrase “shadow enhancers” was coined by Mike Levine and colleagues in a 2008 *Science* Brevia article describing the discovery of remote enhancers of two *Drosophila* genes, *brinker* and *sog* [2]. These enhancers, which drive gene expression in the presumptive neurogenic ectoderm of the early embryo, were identified by chromatin immunoprecipitation (ChIP)-chip assays [3] and validated with transgenic reporters. They share several features: (a) they each drive a pattern of transcription resembling that of a previously identified “primary” enhancer that is more proximal to the promoter being regulated; (b) they bind the same TFs as the primary enhancer, suggesting a similar regulatory logic; and (c) they are located either within an intron of, or on the far side of, a neighboring gene (Fig. 1). In that paper, the term *shadow enhancer* is proposed for “remote

secondary enhancers mapping far from the target gene and mediating activities overlapping the primary enhancer” [2].

Q: Do I have to use that term?

A: As the phrase *shadow enhancers* has swept the field of *cis*-regulation [4–13] and the pop-science blogosphere, some in the field have complained about this new term. One objection I have heard is that the concept itself is nothing new. It is certainly true that apparently redundant enhancers have long been known to regulate certain genes, as I will discuss in more detail below. However, recent work from a number of groups [5, 8, 14–18], most notably those led by Levine and David Stern, moves beyond simply documenting apparent redundancy by testing specific ideas about the functional significance of such a *cis*-regulatory arrangement. Because the concept of shadow enhancers is so tightly associated in the literature with these exciting proposed regulatory and evolutionary mechanisms (as described below), I maintain that the term is not a mere repackaging of the idea of redundancy.

Others have balked, not at the idea of shadow enhancers *per se*, but at the designation of one element as the *primary enhancer* and one (or more) as the *shadow*, with the difference in regulatory significance that those terms seem to imply. Levine recently stated, at the Keystone Symposium on Evolutionary Developmental Biology [19], that the term was meant to refer specifically to elements that reside within or on the far side of a neighboring gene (i.e. “in the shadow” of another gene). Still, because of the perception that *primary* connotes a higher degree of importance, and the potential nomenclatural difficulties of cases in which two enhancers are discovered simultaneously, are equidistant from the promoter, etc., I submit that the idea of designating an individual enhancer as the *primary* or the *shadow* is unsatisfactory and too narrowly applicable. I believe that the term *shadow enhancers* is a useful and memorable way to describe genes containing multiple separable enhancers driving similar patterns of expression. I therefore propose to slightly adjust the definition to describe a regulatory arrangement—a type of gene structure—without assigning the labels *primary* and *shadow* to individual elements. By this revised definition, the neuro-ectodermal enhancers of *sog* could both be considered shadow enhancers: that is, components of a multi-enhancer system regulating the same gene in the same tissue. The individual enhancers could be referred to as proximal and distal, 5’ and 3’, or in many other ways. Ideally, nothing would be implied about the relative importance or functional redundancy of any of the elements.

For researchers who strongly dislike the term and do not accept the above proposal, I offer *distributed enhancers* as a possible substitute. This phrase has the merit of accuracy, as the gene’s *cis*-regulatory information (concerning a specific aspect of its expression pattern) is distributed among multiple modules. However, it can’t be used to refer to an individual enhancer, and it lacks the air of mystery conveyed by *shadow enhancers*.

MAIN TEXT

Q: How many genes have shadow/redundant/distributed enhancers?

A: Of course, we don’t know exactly. Even if we had genome-wide TF binding data from all organisms, for all transcription factors, in all tissue types, at all stages and under all relevant conditions, enhancers must be defined functionally, and such tests have been applied to only a tiny fraction of all possible enhancer sequences. For many loci that have been searched for enhancers, once an element has been found that is largely sufficient to explain a given expression pattern, researchers understandably stop searching.

Nevertheless, there is an extensive literature in vertebrate and invertebrate systems, going back over 20 years, of separable, apparently redundant enhancers (or semi-redundant enhancers, or enhancers capable of driving similar or overlapping patterns) within a single gene (e.g. [3, 6, 9, 12, 20–40]). New evidence indicates that the embryonic patterns of all of the *Drosophila* gap genes are encoded by multiple elements [17]. Still, as discussed below, many gene expression patterns are known to depend on single, non-redundant enhancers.

As interest in *cis*-regulation has grown, especially in the fields of development and evolution, and as tools for genomic manipulation have improved, reports of distributed enhancers have increased over the last few years. Two noteworthy examples, both from *Drosophila*, are the aforementioned *brinker* gene, which, apart from the “shadow” enhancer, contains multiple 5’ enhancers driving similar expression patterns in the embryo and developing wing [35, 41], and the *shavenbaby* gene, which contains six 5’ enhancers driving overlapping expression patterns in the embryonic epidermis [8, 16, 32]. Reports like these comprise a small proportion of the enhancer-identification literature, but as mentioned above, very few loci have been comprehensively scoured to account for all possible *cis*-regulatory inputs. The relatively high frequency of insulator elements between genes [42] might suggest that most genes do not harbor their neighbors’ enhancers, but this remains to be tested. Bioinformatic TF binding site predictions and genome-wide ChIP data, which brought the shadow enhancers of *brinker* and *sog* to light, will be increasingly informative on this question.

Q: How redundant are these distributed enhancers?

A: This depends on how strictly redundancy is defined, which in turn depends on how stringently it is tested experimentally. Enhancer redundancy has been claimed in the absence of in vivo phenotypic assays, in cases where multiple modules are sufficient to drive similar or overlapping patterns of gene expression, usually in transgenic reporter experiments (e.g. [24, 26, 29, 43, 44]). To a geneticist, this would not be considered sufficient proof of redundancy, but from the perspective of sufficiency (as opposed to necessity), two sequences that activate gene expression in the same cell under the same conditions could be considered “informationally” redundant.

In the field of developmental gene regulation, a higher standard for in vivo enhancer redundancy is the demonstration that the loss of one module has no significant observable effect on viability, organ morphology, or some other relevant metric (e.g. [8, 15, 28, 36–38, 45, 46]). For example, Frankel et al. [8] generated a chromosomal deficiency in *Drosophila* that deleted three of six epidermal enhancers of the *shavenbaby* gene; this mutation did not produce a significant loss-of-function phenotype under normal lab conditions. Similarly, Perry et al. [15] removed one of two mesodermal enhancers of the *snail* gene in the context of a bacterial artificial chromosome (BAC) rescue transgene; under normal lab conditions, this mutation had no significant effect on the pattern of gene expression or on the ability of the BAC to rescue gastrulation defects in *snail* mutant embryos. (But more on the redundancy of these shadow enhancers later.) In the mouse, targeted deletion of an enhancer of *Prx1* that is sufficient to drive limb expression caused no developmental limb phenotype [33, 47].

By the same token, it is important to note that many enhancers have been found to be *non*-redundant—i.e. individually required for normal function—by this functional standard. This category includes evidence from in vivo functional tests in genetic model systems [48–57], as well as cases of mutant phenotypes being traced to induced or spontaneous mutations in enhancers (e.g. [51, 58, 59]). There is also a growing number of documented cases of what could be called “enhancer-opathies,” human genetic diseases caused by mutations in *cis*-

regulatory elements (e.g. [12, 50, 60–62]); these enhancers are obviously functionally non-redundant.

Interest in the “shadow enhancer” phenomenon, and a reluctance to accept the idea of a regulatory element whose function is evolutionarily well conserved yet utterly irrelevant to fitness, have recently inspired more stringent tests of the functional requirements for “redundant” enhancers. To return to the cases of *snail* and *shavenbaby*, shadow enhancers in both genes that seemed to be functionally unnecessary in a normal laboratory setting were subsequently shown to be required for normal gene expression and function when fly embryos were placed in sub-optimal conditions, such as high temperatures or a sensitized genetic background [8, 15]. Thus, it is easy to speculate that any report of a functionally redundant enhancer may have overlooked the critical environmental stress, culture condition, behavioral assay, selection criterion, etc., rendering true redundancy essentially unprovable. A new report suggests that the two ventral enhancers of the *snail* gene are functionally non-redundant even under normal culture conditions [18]. Proposed roles for distributed enhancers in maintaining robustness of gene expression in the face of environmental noise will be discussed in a later section.

It is difficult to estimate the ratio of functionally redundant to non-redundant enhancers because of the varying standards of proof mentioned above, and also because of likely publication bias against negative results [63].

Q: What is the function of distributed enhancers?

A: Three functions have been proposed:

1. Robustness

Gene expression levels naturally fluctuate between individuals in a population and between cells in a tissue. Genetic variation and environmental instability can exacerbate these differences. If the expression of a developmental regulator (say, a TF or signaling pathway component) dips below a minimum threshold level, cell fate specification or differentiation will be affected, which can result in a morphological defect. Developmental programs can be buffered against minor variations by maintaining super-threshold expression levels of important regulators (as long as these levels remain below the threshold for triggering gain-of-function defects) [8, 10, 15].

This argument, which provides a mechanism for Waddington’s phenomenon of “canalization of development” [64], is perfectly sound—in fact, given what we know of loss-of-function genetics, it must be correct. For example, diploid multicellular organisms need only one copy of most genes for near-normal viability and fertility, at least under lab conditions, but these heterozygous mutants are more vulnerable to poor culture conditions, and they are far more sensitive to partial loss-of-function of other genes (this is the basis of enhancer-suppressor screens). The question is not whether super-threshold levels of gene expression increase developmental robustness—rather, the question is, why use two (or more) separate enhancers to do the job? One could imagine that one extra-strength enhancer would be just as effective for the purpose, and to me at least this seems like a neater, simpler solution: just add a couple of activator binding sites here, or remove a nucleosome positioning sequence there. Of course, evolution allows any solution that is not forbidden, whether it appeals to human intuition or not, and perhaps genes don’t care whether their *cis*-regulatory information is organized in a way that seems tidy to us. But there may be reasons why two weak enhancers might be preferable to one strong one.

For example, imagine that a given enhancer has a maximum level of activation activity, or a “speed limit,” resulting from biochemical or biophysical constraints. The only way to boost the transcription rate of the gene, outside of adjusting the promoter itself, would be to acquire more enhancers that drive activation in the same pattern (Fig. 2A). This scenario requires that enhancers have a maximum activation level that is below the maximum firing rate of the promoter.

A plausible idea, developed by Levine and colleagues in recent papers [15, 17], is that enhancers have an inherent “failure rate,” the probability that, in a given cell within the domain of expression, a sufficient rate of transcription will not be reached. This was demonstrated at the *snail* and *hunchback* loci of *Drosophila*: BAC reporter genes lacking the “primary” or “shadow” embryonic enhancer show an increased number of “holes” in the gene expression domain (i.e. nuclei with gene expression below a given threshold). If there is no way to reduce the failure rate of a single enhancer to an acceptably low level, adding a second enhancer can solve the problem (Fig. 2B): if one enhancer has a failure rate of 3%, two copies will sufficiently activate the gene in 99.91% of cells.

This model of robustness, or at least the simplest form of this model, seems to make a testable prediction: that boosting the quantitative activity of an enhancer by adding activator binding sites will not reduce the inherent failure rate. If this is not the case, then we return to the original question—why acquire two separate weak enhancers, rather than one sufficiently strong one?

2. Patterning precision

There is also strong evidence that, at least in some cases, quasi-redundant enhancers make important individual patterning contributions, such that the final gene pattern of gene expression depends on multiple *cis* elements (Fig. 2C). Levine’s group demonstrates in a recent report [17] that, for the gap genes *hunchback*, *Krüppel*, and *knirps*, two enhancers are required to draw sharp, consistent stripe boundaries of embryonic gene expression, and also to properly position those boundaries along the anterior-posterior axis. The latter finding implies that, for these genes, the two enhancers employ slightly different *cis*-regulatory logic: this is confirmed by the expression patterns of single-enhancer reporter genes [17]. A similarly multi-modular regulatory circuitry applies to *snail* [18].

Again we can ask, somewhat teleologically: wouldn’t it be simpler to “evolve” a single enhancer that drives the correct pattern? Leaving aside the robustness arguments detailed above, there may be good reasons for such a seemingly complicated arrangement. In vivo reporter experiments have demonstrated that, when two enhancers are brought into close proximity, short-range repressors that set expression boundaries for one enhancer can interfere with the activity of the nearby enhancer, disrupting the final pattern of gene expression to which both enhancers contribute [65–67]. Thus, it is possible that the shadow enhancers of the *Drosophila* gap genes must be kept separate to avoid inappropriate short-range interactions among activators and repressors (Fig. 2D). This model is fairly easily testable.

3. Evolvability

Genetic redundancy has long been considered a potential source of evolutionary innovation [68]. It is increasingly widely recognized that much evolutionary morphological change stems from changes to *cis*-regulatory sequence [19], so it is natural that enhancer redundancy should be proposed as an important mechanism for evolving novel expression patterns (Fig. 2E) [2, 5, 16, 43, 69–72]. I wish to make only two comments on this train of thought. First (with the caveat that I am not a qualified evolutionary theorist), the idea that

genes acquire redundant enhancers *as a means to achieve evolvability* seems to put the cart before the horse. However, I am assured by those who know better that this is not what is actually being proposed: rather, the idea is that traits that facilitate change enhance fitness without requiring evolution to look ahead, and apparently the math works out. Second, if shadow enhancers are not really functionally redundant (see points 1 and 2), then neither enhancer is “free” to modify its expression pattern. This means that for a given set of distributed enhancers, evolvability should be mutually exclusive with essential functions in transcriptional robustness or precision.

Regarding the evolutionary origins of shadow enhancers, there is currently no evidence that they arise by duplication. Therefore, they may differ dramatically from gene duplications, both in the mechanisms that create them and in the evolutionary forces that later shape them.

Q: How modular are enhancers, really?

A: The existence of shadow/redundant/those enhancers might reasonably inspire us to question the idea that enhancers are truly modular, discrete units. It is easy to imagine a gene whose *cis*-regulatory information is spread fairly evenly across the non-coding sequences of the locus, and this would be consistent with some of the findings of enhancer redundancy cited above. Could the concept of a discrete enhancer module largely be an artifact of 30 years of reporter gene experiments that have often focused on sufficiency, rather than necessity?

Those *in vivo* reporter experiments have led to a view of a typical enhancer module that is manageably sized (usually several hundred base pairs in length, when serious efforts at trimming are made) and sufficient to drive a pattern of gene expression resembling one or more aspects of the parent gene’s expression profile. Published maps of enhancers within a gene locus nearly always show them as discrete, labeled boxes (“eye enhancer”; “limb enhancer”; “stripe 2 enhancer”). Generally speaking, such a box describes the “minimal” element (e.g. [73, 74]), typically defined as the shortest sequence that is sufficient to activate easily detectable levels of gene expression (via a short promoter sequence that is silent on its own) in a pattern that is similar or identical to that of the native gene in a given tissue. Less frequently, the minimal element is defined functionally, by its ability to drive rescue transgene expression that suppresses the loss-of-function phenotype of the relevant gene (e.g. [75, 76]).

Veteran enhancer-bashers, and those who carefully read the papers, know that “minimal” enhancer fragments do not always perfectly replicate the precise spatial boundaries of expression of the native gene, and that the most minimal fragment that can reproduce a given pattern often drives lower levels of gene expression than more extensive fragments (Fig. 1; [25, 74, 76–82]). Certain complex multigenic loci, such as Hox clusters and the β -globin locus, defy analysis by traditional sufficiency-based reporter gene assays [83–86]. Is individual enhancer analysis useful or appropriate for the study of genes with shadow/redundant/distributed enhancers?

CONCLUSIONS

Q: Given all of the above, is it useful to study a single enhancer in isolation?

A: It depends on the type of question one is trying to answer. If the goal is to unravel higher-order *cis*-regulation at a complex gene locus, in which multiple elements interact, synergize, or interfere with one another, the study of isolated modules is clearly insufficient. Tools for large-scale genetic manipulation, which are required to effectively tackle this type of problem, have dramatically improved in recent years [34, 85, 87–90].

Still, we owe almost all of what we know about *cis*-regulatory logic to fine-scale functional analyses of individual enhancers, mostly employing transgenic reporter assays to determine what is sufficient, at the DNA sequence level, to specify proper patterning of gene expression. If rescue BAC deletion analyses and targeted in situ enhancer mutations had been available 30 years ago, and if they were the only tools available to the field, the entire problem of transcriptional regulation might have been given up as hopelessly complex. By reducing the scale of the problem to a short sequence that is capable of driving a specific (if not always a perfectly precise or robust) pattern of gene expression in vivo, we have made remarkable advances in our understanding of the logic of transcriptional networks and their evolution, and I believe we will continue to do so, even in the era of systems biology. By simultaneously attacking the problem at the genomic scale, the gene-locus scale, and the reductionist scale of individual *cis*-regulatory modules and TF binding sites, the field can now make even faster leaps forward.

Acknowledgments

I am supported by NIH grant GM076509 and a Center for Organogenesis Research Team Award. I am grateful to Mike Levine and David Stern for helpful discussions and critiques.

Abbreviations

BAC	bacterial artificial chromosome
ChIP	chromatin immunoprecipitation
TF	transcription factor

REFERENCES

1. Levine M. Transcriptional enhancers in animal development and evolution. *Curr Biol.* 2010; 20:R754–R763. [PubMed: 20833320]
2. Hong JW, Hendrix DA, Levine MS. Shadow enhancers as a source of evolutionary novelty. *Science.* 2008; 321:1314. [PubMed: 18772429]
3. Zeitlinger J, Zinzen RP, Stark A, Kellis M, et al. Whole-genome ChIP-chip analysis of Dorsal, Twist, and Snail suggests integration of diverse patterning processes in the *Drosophila* embryo. *Genes Dev.* 2007; 21:385–390. [PubMed: 17322397]
4. Wray GA, Babbitt CC. Enhancing gene regulation. *Science.* 2008; 321:1300–1301. [PubMed: 18772422]
5. Cande J, Goltsev Y, Levine MS. Conservation of enhancer location in divergent insects. *Proc Natl Acad Sci USA.* 2009; 106:14414–14419. [PubMed: 19666595]
6. O'Meara MM, Bigelow H, Flibotte S, Etchberger JF, et al. *Cis*-regulatory mutations in the *Caenorhabditis elegans* homeobox gene locus *cog-1* affect neuronal development. *Genetics.* 2009; 181:1679–1686. [PubMed: 19189954]
7. Corbo JC, Lawrence KA, Karlstetter M, Myers CA, et al. CRX ChIP-seq reveals the *cis*-regulatory architecture of mouse photoreceptors. *Genome Res.* 2010; 20:1512–1525. [PubMed: 20693478]
8. Frankel N, Davis GK, Vargas D, Wang S, et al. Phenotypic robustness conferred by apparently redundant transcriptional enhancers. *Nature.* 2010; 466:490–493. [PubMed: 20512118]
9. Guerrero L, Marco-Ferreres R, Serrano AL, Arredondo JJ, et al. Secondary enhancers synergise with primary enhancers to guarantee fine-tuned muscle gene expression. *Dev Biol.* 2010; 337:16–28. [PubMed: 19835855]
10. Hobert O. Gene regulation: enhancers stepping out of the shadow. *Curr Biol.* 2010; 20:R697–R699. [PubMed: 20833307]
11. Swami M. Transcription: Shadow enhancers confer robustness. *Nat Rev Genet.* 2010; 11:454. [PubMed: 20548292]

12. Ghiasvand NM, Rudolph DD, Mashayekhi M, Brzezinski JA 4th, et al. Deletion of a remote enhancer near *ATOH7* disrupts retinal neurogenesis, causing NCRNA disease. *Nat Neurosci*. 2011; 14:578–586. [PubMed: 21441919]
13. Watts JA, Zhang C, Klein-Szanto AJ, Kormish JD, et al. Study of FoxA pioneer factor at silent genes reveals Rfx-repressed enhancer at *Cdx2* and a potential indicator of esophageal adenocarcinoma development. *PLoS Genet*. 2011; 7:e1002277. [PubMed: 21935353]
14. Perry MW, Cande JD, Boettiger AN, Levine M. Evolution of insect dorsoventral patterning mechanisms. *Cold Spring Harb Symp Quant Biol*. 2009; 74:275–279. [PubMed: 19843594]
15. Perry MW, Boettiger AN, Bothma JP, Levine M. Shadow enhancers foster robustness of *Drosophila* gastrulation. *Curr Biol*. 2010; 20:1562–1567. [PubMed: 20797865]
16. Frankel N, Erezylmaz DF, McGregor AP, Wang S, et al. Morphological evolution caused by many subtle-effect substitutions in regulatory DNA. *Nature*. 2011; 474:598–603. [PubMed: 21720363]
17. Perry MW, Boettiger AN, Levine M. Multiple enhancers ensure precision of gap gene-expression patterns in the *Drosophila* embryo. *Proc Natl Acad Sci USA*. 2011; 108:13570–13575. [PubMed: 21825127]
18. Dunipace L, Ozdemir A, Stathopoulos A. Complex interactions between *cis*-regulatory modules in native conformation are critical for *Drosophila snail* expression. *Development*. 2011; 138:4075–4084. [PubMed: 21813571]
19. Haag ES, Lenski RE. L'enfant terrible at 30: the maturation of evolutionary developmental biology. *Development*. 2011; 138:2633–2637. [PubMed: 21652645]
20. Jongens TA, Fowler T, Shermoen AW, Beckendorf SK. Functional redundancy in the tissue-specific enhancer of the *Drosophila* Sgs-4 gene. *Embo J*. 1988; 7:2559–2567. [PubMed: 3142764]
21. Hoch M, Schroder C, Seifert E, Jackle H. *cis*-acting control elements for *Krüppel* expression in the *Drosophila* embryo. *Embo J*. 1990; 9:2587–2595. [PubMed: 2114978]
22. Kassiss JA. Spatial and temporal control elements of the *Drosophila engrailed* gene. *Genes Dev*. 1990; 4:433–443. [PubMed: 2110923]
23. Camprodón FJ, Castelli-Gair JE. Ultrabithorax protein expression in breakpoint mutants: localization of single, co-operative and redundant *cis* regulatory elements. *Dev Genes Evol*. 1994; 203:411–421.
24. Shashikant CS, Ruddle FH. Combinations of closely situated *cis*-acting elements determine tissue-specific patterns and anterior extent of early *Hoxc8* expression. *Proc Natl Acad Sci USA*. 1996; 93:12364–12369. [PubMed: 8901587]
25. Bachmann A, Knust E. Dissection of *cis*-regulatory elements of the *Drosophila* gene Serrate. *Dev Genes Evol*. 1998; 208:346–351. [PubMed: 9716725]
26. Nakada Y, Parab P, Simmons A, Omer-Abdalla A, et al. Separable enhancer sequences regulate the expression of the neural bHLH transcription factor neurogenin 1. *Dev Biol*. 2004; 271:479–487. [PubMed: 15223348]
27. Schroeder MD, Pearce M, Fak J, Fan H, et al. Transcriptional control in the segmentation gene network of *Drosophila*. *PLoS Biol*. 2004; 2:E271. [PubMed: 15340490]
28. Pappu KS, Ostrin EJ, Middlebrooks BW, Sili BT, et al. Dual regulation and redundant function of two eye-specific enhancers of the *Drosophila* retinal determination gene *dachshund*. *Development*. 2005; 132:2895–2905. [PubMed: 15930118]
29. Jeong Y, El-Jaick K, Roessler E, Muenke M, et al. A functional screen for *sonic hedgehog* regulatory elements across a 1 Mb interval identifies long-range ventral forebrain enhancers. *Development*. 2006; 133:761–772. [PubMed: 16407397]
30. Ertzer R, Müller F, Hadzhiev Y, Rathnam S, et al. Cooperation of *sonic hedgehog* enhancers in midline expression. *Dev Biol*. 2007; 301:578–589. [PubMed: 17157288]
31. Gonzalez F, Duboule D, Spitz F. Transgenic analysis of *Hoxd* gene regulation during digit development. *Dev Biol*. 2007; 306:847–859. [PubMed: 17448461]
32. McGregor AP, Orgogozo V, Delon I, Zanet J, et al. Morphological evolution through multiple *cis*-regulatory mutations at a single gene. *Nature*. 2007; 448:587–590. [PubMed: 17632547]
33. Cretekos CJ, Wang Y, Green ED, Martin JF, et al. Regulatory divergence modifies limb length between mammals. *Genes Dev*. 2008; 22:141–151. [PubMed: 18198333]

34. Lehoczy JA, Innis JW. BAC transgenic analysis reveals enhancers sufficient for *Hoxa13* and neighborhood gene expression in mouse embryonic distal limbs and genital bud. *Evol Dev.* 2008; 10:421–432. [PubMed: 18638319]
35. Yao LC, Phin S, Cho J, Rushlow C, et al. Multiple modular promoter elements drive graded *brinker* expression in response to the Dpp morphogen gradient. *Development.* 2008; 135:2183–2192. [PubMed: 18506030]
36. Zhou X, Sigmund CD. Chorionic enhancer is dispensable for regulated expression of the human *renin* gene. *Am J Physiol Regul Integr Comp Physiol.* 2008; 294:R279–R287. [PubMed: 18077515]
37. Bébin AG, Carrion C, Marquet M, Cogné N, et al. In vivo redundant function of the 3' *IgH* regulatory element HS3b in the mouse. *J Immunol.* 2010; 184:3710–3717. [PubMed: 20176739]
38. Degenhardt KR, Milewski RC, Padmanabhan A, Miller M, et al. Distinct enhancers at the *Pax3* locus can function redundantly to regulate neural tube and neural crest expressions. *Dev Biol.* 2010; 339:519–527. [PubMed: 20045680]
39. Friedli M, Barde I, Arcangeli M, Verp S, et al. A systematic enhancer screen using lentivector transgenesis identifies conserved and non-conserved functional elements at the *Olig1* and *Olig2* locus. *PLoS One.* 2010; 5:e15741. [PubMed: 21206754]
40. Kalay G, Wittkopp PJ. Nomadic enhancers: tissue-specific *cis*-regulatory elements of *yellow* have divergent genomic positions among *Drosophila* species. *PLoS Genet.* 2010; 6:e1001222. [PubMed: 21151964]
41. Müller B, Hartmann B, Pyrowolakis G, Affolter M, et al. Conversion of an extracellular Dpp/BMP morphogen gradient into an inverse transcriptional gradient. *Cell.* 2003; 113:221–233. [PubMed: 12705870]
42. Nègre N, Brown CD, Shah PK, Kheradpour P, et al. A comprehensive map of insulator elements for the *Drosophila* genome. *PLoS Genet.* 2010; 6:e1000814. [PubMed: 20084099]
43. Abbasi AA, Paparidis Z, Malik S, Bangs F, et al. Human intronic enhancers control distinct sub-domains of *Gli3* expression during mouse CNS and limb development. *BMC Dev Biol.* 2010; 10:44. [PubMed: 20426846]
44. Busch MA, Bombliks K, Weigel D. Activation of a floral homeotic gene in *Arabidopsis*. *Science.* 1999; 285:585–587. [PubMed: 10417388]
45. Chen JC, Ramachandran R, Goldhamer DJ. Essential and redundant functions of the *MyoD* distal regulatory region revealed by targeted mutagenesis. *Dev Biol.* 2002; 245:213–223. [PubMed: 11969267]
46. Xiong N, Kang C, Raulet DH. Redundant and unique roles of two enhancer elements in the *TCR γ* locus in gene regulation and $\gamma\delta$ T cell development. *Immunity.* 2002; 16:453–463. [PubMed: 11911829]
47. Martin JF, Olson EN. Identification of a *prx1* limb enhancer. *Genesis.* 2000; 26:225–229. [PubMed: 10748458]
48. Liu Q, Bungert J, Engel JD. Mutation of gene-proximal regulatory elements disrupts human ϵ -, γ -, and β -globin expression in yeast artificial chromosome transgenic mice. *Proc Natl Acad Sci USA.* 1997; 94:169–174. [PubMed: 8990180]
49. Pfeffer PL, Payer B, Reim G, di Magliano MP, et al. The activation and maintenance of *Pax2* expression at the mid-hindbrain boundary is controlled by separate enhancers. *Development.* 2002; 129:307–318. [PubMed: 11807024]
50. Loots GG, Kneissel M, Keller H, Baptist M, et al. Genomic deletion of a long-range bone enhancer misregulates *sclerostin* in Van Buchem disease. *Genome Res.* 2005; 15:928–935. [PubMed: 15965026]
51. Sagai T, Hosoya M, Mizushima Y, Tamura M, et al. Elimination of a long-range *cis*-regulatory module causes complete loss of limb-specific *Shh* expression and truncation of the mouse limb. *Development.* 2005; 132:797–803. [PubMed: 15677727]
52. Murisier F, Guichard S, Beermann F. Distinct distal regulatory elements control *tyrosinase* expression in melanocytes and the retinal pigment epithelium. *Dev Biol.* 2007; 303:838–847. [PubMed: 17196956]

53. Delporte FM, Pasque V, Devos N, Manfroid I, et al. Expression of zebrafish *pax6b* in pancreas is regulated by two enhancers containing highly conserved *cis*-elements bound by PDX1, PBX and PREP factors. *BMC Dev Biol.* 2008; 8:53. [PubMed: 18485195]
54. Xiang Y, Garrard WT. The downstream transcriptional enhancer, Ed, positively regulates mouse *Igκ* gene expression and somatic hypermutation. *J Immunol.* 2008; 180:6725–6732. [PubMed: 18453592]
55. Feng HZ, Wei B, Jin JP. Deletion of a genomic segment containing the *cardiac troponin I* gene knocks down expression of the *slow troponin T* gene and impairs fatigue tolerance of diaphragm muscle. *J Biol Chem.* 2009; 284:31798–31806. [PubMed: 19797054]
56. Sagai T, Amano T, Tamura M, Mizushima Y, et al. A cluster of three long-range enhancers directs regional *Shh* expression in the epithelial linings. *Development.* 2009; 136:1665–1674. [PubMed: 19369396]
57. McMullin RP, Dobi A, Mutton LN, Orosz A, et al. A FOXA1-binding enhancer regulates *Hoxb13* expression in the prostate gland. *Proc Natl Acad Sci USA.* 2010; 107:98–103. [PubMed: 20018680]
58. Davison D, Chapman CH, Wedeen C, Bingham PM. Genetic and physical studies of a portion of the *white* locus participating in transcriptional regulation and in synapsis-dependent interactions in *Drosophila* adult tissues. *Genetics.* 1985; 110:479–494. [PubMed: 2991082]
59. Fu W, Duan H, Frei E, Noll M. *shaven* and *sparkling* are mutations in separate enhancers of the *Drosophila Pax2* homolog. *Development.* 1998; 125:2943–2950. [PubMed: 9655816]
60. Kleinjan DA, van Heyningen V. Long-range control of gene expression: emerging mechanisms and disruption in disease. *Am J Hum Genet.* 2005; 76:8–32. [PubMed: 15549674]
61. Epstein DJ. *Cis*-regulatory mutations in human disease. *Brief Funct Genomic Proteomic.* 2009; 8:310–316. [PubMed: 19641089]
62. Sabherwal N, Bangs F, Roth R, Weiss B, et al. Long-range conserved non-coding *SHOX* sequences regulate expression in developing chicken limb and are associated with short stature phenotypes in human patients. *Hum Mol Genet.* 2007; 16:210–222. [PubMed: 17200153]
63. Matias-Guiu J, Garcia-Ramos R. Editorial bias in scientific publications. *Neurologia.* 2011; 26:1–5. [PubMed: 21216501]
64. Waddington CH. Canalization of development and the inheritance of acquired characters. *Nature.* 1942; 150:563–565.
65. Small S, Arnosti DN, Levine M. Spacing ensures autonomous expression of different stripe enhancers in the *even-skipped* promoter. *Development.* 1993; 119:762–772. [PubMed: 8187640]
66. Gray S, Levine M. Short-range transcriptional repressors mediate both quenching and direct repression within complex loci in *Drosophila*. *Genes Dev.* 1996; 10:700–710. [PubMed: 8598297]
67. Gray S, Levine M. Transcriptional repression in development. *Curr Opin Cell Biol.* 1996; 8:358–364. [PubMed: 8743887]
68. Kirschner M, Gerhart J. Evolvability. *Proc Natl Acad Sci USA.* 1998; 95:8420–8427. [PubMed: 9671692]
69. Hadzhiev Y, Lang M, Ertzer R, Meyer A, et al. Functional diversification of *sonic hedgehog* paralog enhancers identified by phylogenomic reconstruction. *Genome Biol.* 2007; 8:R106. [PubMed: 17559649]
70. Meireles-Filho AC, Stark A. Comparative genomics of gene regulation-conservation and divergence of *cis*-regulatory information. *Curr Opin Genet Dev.* 2009; 19:565–570. [PubMed: 19913403]
71. Paixão T, Azevedo RB. Redundancy and the evolution of *cis*-regulatory element multiplicity. *PLoS Comput Biol.* 2010; 6:e1000848. [PubMed: 20628617]
72. Uemura O, Okada Y, Ando H, Guedj M, et al. Comparative functional genomics revealed conservation and diversification of three enhancers of the *isll* gene for motor and sensory neuron-specific expression. *Dev Biol.* 2005; 278:587–606. [PubMed: 15680372]
73. Costa RH, Lai E, Grayson DR, Darnell JE Jr. The cell-specific enhancer of the mouse *transthyretin* (prealbumin) gene binds a common factor at one site and a liver-specific factor(s) at two other sites. *Mol Cell Biol.* 1988; 8:81–90. [PubMed: 3336368]

74. Small S, Blair A, Levine M. Regulation of *even-skipped* stripe 2 in the *Drosophila* embryo. *EMBO J.* 1992; 11:4047–4057. [PubMed: 1327756]
75. Flores GV, Duan H, Yan H, Nagaraj R, et al. Combinatorial signaling in the specification of unique cell fates. *Cell.* 2000; 103:75–85. [PubMed: 11051549]
76. Milewski RC, Chi NC, Li J, Brown C, et al. Identification of minimal enhancer elements sufficient for *Pax3* expression in neural crest and implication of Tead2 as a regulator of *Pax3*. *Development.* 2004; 131:829–837. [PubMed: 14736747]
77. Jiang J, Kosman D, Ip YT, Levine M. The *dorsal* morphogen gradient regulates the mesoderm determinant *twist* in early *Drosophila* embryos. *Genes Dev.* 1991; 5:1881–1891. [PubMed: 1655572]
78. Sasaki H, Hogan BL. Enhancer analysis of the mouse *HNF-3 beta* gene: regulatory elements for node/notochord and floor plate are independent and consist of multiple sub-elements. *Genes Cells.* 1996; 1:59–72. [PubMed: 9078367]
79. Davis GK, Srinivasan DG, Wittkopp PJ, Stern DL. The function and regulation of *Ultrabithorax* in the legs of *Drosophila melanogaster*. *Dev Biol.* 2007; 308:621–631. [PubMed: 17640629]
80. Irvine SQ, Fonseca VC, Zompa MA, Antony R. *Cis*-regulatory organization of the *Pax6* gene in the ascidian *Ciona intestinalis*. *Dev Biol.* 2008; 317:649–659. [PubMed: 18342846]
81. Swanson CI, Evans NC, Barolo S. Structural rules and complex regulatory circuitry constrain expression of a Notch- and EGFR-regulated eye enhancer. *Dev Cell.* 2010; 18:359–370. [PubMed: 20230745]
82. Barrière A, Gordon KL, Ruvinsky I. Distinct functional constraints partition sequence conservation in a *cis*-regulatory element. *PLoS Genet.* 2011; 7:e1002095. [PubMed: 21655084]
83. Mann RS. Why are Hox genes clustered? *BioEssays.* 1997; 19:661–664. [PubMed: 9264246]
84. Li Q, Peterson KR, Fang X, Stamatoyannopoulos G. Locus control regions. *Blood.* 2002; 100:3077–3086. [PubMed: 12384402]
85. Maeda RK, Karch F. Gene expression in time and space: additive vs hierarchical organization of *cis*-regulatory regions. *Curr Opin Genet Dev.* 2011; 21:187–193. [PubMed: 21349696]
86. Kwon D, Mucci D, Langlais KK, Americo JL, et al. Enhancer-promoter communication at the *Drosophila engrailed* locus. *Development.* 2009; 136:3067–3075. [PubMed: 19675130]
87. Venken KJ, Carlson JW, Schulze KL, Pan H, et al. Versatile P[acman] BAC libraries for transgenesis studies in *Drosophila melanogaster*. *Nat Methods.* 2009; 6:431–434. [PubMed: 19465919]
88. Galindo MI, Fernández-Garza D, Phillips R, Couso JP. Control of *Distal-less* expression in the *Drosophila* appendages by functional 3' enhancers. *Dev Biol.* 2011; 353:396–410. [PubMed: 21320482]
89. Gao G, McMahon C, Chen J, Rong YS. A powerful method combining homologous recombination and site-specific recombination for targeted mutagenesis in *Drosophila*. *Proc Natl Acad Sci USA.* 2008; 105:13999–14004. [PubMed: 18772376]
90. Iampietro C, Gummalla M, Mutero A, Karch F, et al. Initiator elements function to determine the activity state of BX-C enhancers. *PLoS Genet.* 2010; 6:e1001260. [PubMed: 21203501]

Figure 1.

Diagram of a hypothetical gene locus, illustrating how multiple distributed *cis*-regulatory modules can contribute to total expression of the *green* gene. For the purposes of this diagram, patterning is ignored, and output is considered purely quantitatively. Only regulatory elements of *green* are shown; although "shadow" enhancer D is nearer to the *red* gene, it specifically regulates *green*. Percentages refer to the amount of gene expression driven by each element or combination of elements, relative to the entire gene locus.

Figure 2.

Possible mechanisms for the function and evolution of distributed enhancers. **A:** “Speed limit”: if a single module drives a sub-optimal rate of transcription, multiple modules may be required. **B:** “Failure rate”: if a given enhancer fails to activate transcription in a fraction of cells, a second, independently acting enhancer may significantly improve fidelity of gene expression. **C:** Patterning precision: two modules with overlapping patterns, but different regulatory logic, combine to produce a novel, refined gene expression pattern. **D:** Short-range modular interference: two enhancer modules may require a physical separation to prevent undesirable short-range positive and negative transcription factor interactions

between the two modules. **E:** Evolvability: enhancer redundancy may create opportunities for the generation of novel patterns of gene expression. See text for a fuller discussion of these concepts.

\$watermark-text

\$watermark-text

\$watermark-text